Items 1-50 of 58

per page
Set Descending Direction
Catalog No.
Product Name
Product Information
Product Citation
  1. HSP90 inhibitor

    17-AAG is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90.
  2. Hsp90 inhibitor

    17-DMAG is a water-soluble analog of 17-AAG and geldanamycin that binds the ATP binding site of Hsp90 and inhibits its chaperone activity. Displays more potent antitumor activity than 17-AAG.
  3. HSP90 inhibitor

    BIIB021 is an oral fully synthetic Hsp90 inhibitor that selectively and potently inhibits the molecular chaperone Hsp90 thereby inhibiting the proper assembly of multiple oncogenic proteins involved in tumor growth and survival.
  4. Elesclomol induces oxidative stress by provoking a buildup of reactive oxygen species within cancer cells.
  5. HSP90 Inhibitor

    AUY922 (NVP-AUY922) is highly potent and oral inhibitor of Hsp90 with IC50=21 nM in Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 average 9 nM.
  6. HSP90 Inhibitor

    NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH2-terminal ATP-binding pocket of Hsp90.
  7. Hsp90 inhibitor

    Geldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 μM) and inhibits its chaperone activity.
  8. HSP90 Inhibitor

    AT13387 is a targeted inhibitor of Hsp90,inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival.
  9. Hsp90 inhibitor

    PF-04929113 (SNX-5422) is orally bioavailable heat shock protein 90 (Hsp90) inhibitor.
  10. Hsp90 Inhibitor

    PU-H71 is a potent Hsp90 inhibitor (IC50 = 50 nM).
  11. Hsp90 inhibitor

    MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
  12. Hsp90 inhibitor

    SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor with anticancer properties currently in clinical trials. SNX-2112 induced autophagy in a time- and dose-dependent manner via Akt/mTOR/p70S6K inhibition. SNX-2112 induces significant apoptosis and autophagy in human melanoma A-375 cells, and may be an effective targeted therapy agent

  13. HSP90 inhibitor

    KW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.

  14. HSP90 Inhibitor

    XL888 is an orally bioavailable, ATP-competitive, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
  15. Hsp90 inhibitor

    IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90).
  16. HSP90 inhibitor

    IPI-493 is a potent and orally bioavailable HSP90 inhibitor with Ki of 21 nM.
  17. Hsp90 inhibitor

    Ganetespib is a potent, synthetic, small molecule inhibitor of Hsp90, a chaperone protein that is essential to the function of certain other proteins that drive the growth, proliferation, and survival of many different types of cancer.
  18. Hsp90/SRC/COX-2 Inhibitor

    Radicicol is a potent inhibitor of Hsp90, SRC, and Cox-2
  19. HSP70 Inhibitor

    Occupies mortalin-2 (mot-2), a member of the Hsp70 family, at its p53 binding site and enables p53 translocation to the nucleus. Selectively cytotoxic; causes growth arrest of cancer cells in culture. Also inhibits telomerase activity and cross-links F-actin.
  20. CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction.
  21. HSP90 inhibitor

    Debio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
  22. HSF1 activation inhibitor

    Rocaglamide (Rocaglamide A) is isolated from the genus Aglaia and can be used to treat coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
  23. HSP90 Inhibitor

    HSP990 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.
  24. GA mitochondrial matrix inhibitor

    Gamitrinib TPP is a GA mitochondrial matrix inhibitor. Gamitrinib TPP is offered as the hexafluorophosphate salt.

  25. HSP 70 inhibitor

    VER 155008 is a small molecule, ATP-derivative inhibitor of HSP70 (IC50 = 500 nM).
  26. HSP90-calcineurin-NFAT inhibitor

    YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to heat shock protein 90 (HSP90) with an IC50 of 820 nM on NFAT nuclear translocation.
  27. Geranylgeranylacetone can induce expression of HSP70, HSPB8, and HSPB1.
  28. Hsp90 inhibitor

    VER-49009 is a pyrazole compound that inhibits Hsp90 with an IC50 value of 47 nM.
  29. Hsp90 inhibitor

    VER-50589 is an isoxazole compound that inhibits Hsp90 with an IC50 value of 21 nM.
  30. Grp94 Inhibitor

    PU-WS13 is a potent, Grp94-specific Hsp90 inhibitor of the purine scaffold class. PU-WS13 is a cell-permeable inhibitor of Grp94 with EC50 of 220 nM.
  31. HSP90 inhibitor

    CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.
  32. HSP90 inhibitor

    NMS-E973 is a potent and selective Hsp90 inhibitor.
  33. pan-HSP inhibitor

    KNK437, dose-dependently inhibited the acquisition of thermotolerance and the induction of various HSPs including HSP105, HSP70, and HSP40 in COLO 320DM (human colon carcinoma) cells.
  34. Hsp90 inhibitor

    Alvespimycin is a selective Hsp90 inhibitor with a GI50 of 53 nM.
  35. Hsp90 inhibitor

    Retaspimycin is a potent and water-soluble inhibitor of Hsp90, with EC50s of 119 nM for both Hsp90 and Grp9.
  36. HSP90 inhibitor

    Gedunin, a naturally occurring Hsp90 inhibitor, is tetranortriterpenoid isolated from the Indian neem tree (Azadirachta indica).
  37. HSP90 inhibitor

    Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 activity with IC50 value of μM by binding to the ATP-binding site.
  38. HSP70 inducer

    TRC 051384, belonging to substituted 2-propen-1-one class, is a potent inducer of heat shock protein 70 (HSP70) [1]. Induction of HSP70 is a natural response of stressed cells that protects neuronal cells from a variety of insults including acute ischemia.
  39. HSP90 inhibitor

    EC 144 is a potent inhibitor of the heat shock protein 90 and was found to be effective in tumor growth suppression.
  40. HSF inhibitor

    KRIBB11 is an inhibitor of Heat shock factor (HSF) inhibitor, with IC50 of 1.2 μM.
  41. Antioxidant

    Ethoxyquin is an antioxidant that is widely used in animal feed to protect against lipid peroxidation and fat rancidity in chicken, salmon, and beef.
  42. HSF1 Activator

    HSF1A is a cell-permeable activator of heat shock transcription factor 1 (HSF1).
  43. Hsp70 inducer

    TRC051384 is an inducer of heat shock protein Hsp70.
  44. Hsp47 inhibitor

    Col003 is a potent inhibitor of Hsp47, competitively binds to the collagen binding site on Hsp47 (IC50, 1.8 μM), and inhibits collagen secretion by destabilizing the collagen triple helix.
  45. Hsp70 inhibitor

    JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages.
  46. cell motility and cell invasion inhibitor

    KBU2046 is an oral, highly selective inhibitor of cell motility and cell invasion in vitro. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all of the hallmarks of classical HSP90 inhibitors. KBU2046 inhibits cancer metastasis and prolongs life.
  47. HSP27 inhibitor

    HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof.
  48. Hsp90 inhibitor

    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
  49. Hsp90-Cdc37 interaction disruptors

    Hsp90-Cdc37-IN-1 is an Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance, with an IC50 of 140 nM.
  50. HSP90α/HSP90β inhibitor

    TAS-116 is an oral bioavailable, ATP-competitive, highly specific HSP90α/HSP90β inhibitor (Kis of 34.7 nM and 21.3 nM, respectively) without inhibiting other HSP90 family proteins such as GRP94. TAS-116 demonstrates less ocular toxicity.

Items 1-50 of 58

per page
Set Descending Direction